Neurona’s brain stem cell therapy shows early efficacy in epilepsy
Neurona Therapeutics reported encouraging data from the first two patients dosed with its regenerative stem cell therapy for epilepsy. One…
All articles by William Newton
William Newton
@WillNewton19
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
-
-
Metformin could reduce long Covid rates, large study finds
The anti-diabetic drug metformin, when taken at the time of Covid-19 infection, could reduce the rate of long Covid-19, a…
-
VistaGen’s nasal spray could reduce menopausal hot flashes, new data suggests
A neuroactive nasal spray could reduce hot flashes during menopause, according to new data from VistaGen Therapeutics. In a 36-patient…
-
ASCO 2023: Precigen reports positive early data for CAR-T therapy
New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer. In Phase I…
-
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New Phase IIb data suggests a combination therapy of Akero Therapeutics’s efruxifermin and Novo Nordisk’s Ozempic (semaglutide) can reduce liver…
-
Pharma industry mixed on outlook of decentralised trials
Decentralised clinical trials (DCTs) have been heralded as the clearcut future of pharma clinical research. But a panel of industry…
-
Pharma world braces for major changes in new era of AI
In the aftermath of the Covid-19 pandemic, a new surge in artificial intelligence (AI) technology is beginning to jolt the…
-
China-based HanX earns FDA greenlight for US lymphoma trial
HanX Biopharmaceuticals is gearing up to begin a Phase I/II trial in relapsed/refractory lymphoma after gaining a regulatory nod from…
-
Nexcella reports new data for CAR-T therapy in AL amyloidosis
Nexcella becomes the latest biotech to generate positive cell therapy data with interim early-stage results in light chain (AL) amyloidosis.…
-
Galera earns key FDA designation for pancreatic cancer drug
Galera Therapeutics’s pancreatic cancer program has gained an important boost after the US Food and Drug Administration (FDA) granted rucosopasem…